Tempest Therapeutics (TPST) analyst forecast and price target
Analyst forecast
Consensus of 1 analyst rating
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Upgraded | Neutral → Buy | $11.00 | Jan 22, 2026 |
| HC Wainwright & Co. | Downgraded | Buy → Neutral | $16.00 | Apr 10, 2025 |
| Scotiabank | Downgraded | Sector Outperform → Sector Perform | $9.00 from $7.00 | Apr 10, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $16.00 from $47.00 | Mar 28, 2025 |
| Scotiabank | Maintained | Sector Outperform | $7.00 from $13.00 | Mar 28, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $47.00 | Nov 13, 2024 |
| Piper Sandler | Maintained | Overweight | $5.00 from $8.00 | Nov 13, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $47.00 | Oct 10, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $47.00 | Aug 15, 2024 |
| Piper Sandler | Maintained | Overweight | $8.00 | Jun 21, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $47.00 | Jun 20, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $47.00 | May 13, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $47.00 | May 10, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $47.00 | Mar 20, 2024 |
| Scotiabank | Initiated Coverage | Sector Outperform | $13.00 | Mar 14, 2024 |
| Scotiabank | Initiated Coverage | Sector Outperform | $13.00 | Mar 13, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $47.00 | Mar 12, 2024 |
| Jefferies | Initiated Coverage | Buy | $15.00 | Feb 8, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $47.00 from $35.00 | Oct 11, 2023 |
| HC Wainwright & Co. | Maintained | Buy | $35.00 | Aug 11, 2023 |
Frequently asked questions
Is TPST a buy, sell, or hold?
Analysts covering Tempest Therapeutics currently average a Buy rating: 1 buy, 0 hold and 0 sell, from 1 analyst. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on TPST?
On Jan 22, 2026, HC Wainwright & Co. upgraded Tempest Therapeutics to Buy with a price target of $11.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.